AcesoStem Biostrategies
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AcesoStem Biostrategies - overview
Established
2019
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2019 by Professor Hyuncheol Cho, AcesoStem Biostrategies operates as a research and development company that develops therapies for intractable musculoskeletal disorders. In June 2026, AcesoStem Biostrategies raised KRW 4 billion in series A funding from new investor Premier Partners. AcesoStem Biostrategies developing therapy based on smump cell is an umbilical cord-derived cell without aging and low immunogenicity and high immunomodulatory ability even in a pro-inflammatory lesion environment. It also develops cell tuning technology, including conditioning technology for cells and lesions.
The company will use the June 2026 funding to accelerate the phase 1/2a clinical trial of its rotator cuff, enter non-clinical and clinical trials for osteoarthritis treatments, and establish a new research and development center.
Current Investors
Seoul Technology Holdings, BlissVine Ventures, Tap Angel Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
AcesoStem Biostrategies - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.